ADT (Standard of Care)

DRUG2 trials

Sponsors

Aragon Pharmaceuticals, Inc., UNICANCER

Conditions

High Risk Prostate CarcinomaProstate CancerProstatic Neoplasms

Phase 3

Study Evaluating the Efficacy and Safety of Darolutamide and Stereotactic Dose Escalated Radiotherapy in Patients With Localized Prostate Cancer and High-risk Features of Relapse

RecruitingNCT06625970

UNICANCERHigh Risk Prostate Carcinoma, Prostate Cancer

Start: 2025-04-10End: 2045-10-01Target: 700Updated: 2026-07-31

Unknown Phase

An Expanded Access Protocol for Apalutamide Treatment of Participants With Non-Metastatic Castration-Resistant Prostate Cancer

Aragon Pharmaceuticals, Inc.Prostatic Neoplasms

Updated: 2025-12-10

Related Papers

Randomized phase III trial with a factorial design assessing the efficacy and safety of darolutamide and stereotactic dose-escalated radiotherapy in patients with high-risk localized prostate cancer: the PEACE 7 (GETUG-AFU 45) study protocol

BMC Cancer2026-09-18